BioSight
Companies
TG THERAPEUTICS, INC. logo

TGTX

NASDAQNEW YORK, NY
TG THERAPEUTICS, INC.

TG Therapeutics develops small-molecule and monoclonal antibody treatments for diseases including multiple sclerosis, cancer, and autoimmune conditions. The company has one FDA-approved product, BRIUMVI (ublituximab-xiiy), used to treat relapsing forms of multiple sclerosis, and is working to expand its commercial presence while advancing additional drug candidates through preclinical studies and clinical trials.

Price history not yet available for TGTX.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar